# NCT04429087 (NCT04429087)

> A Study to Test Different Doses of Obrixtamig in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04429087
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Boehringer Ingelheim
- Conditions: Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3
- Interventions: Obrixtamig - parenteral 1; Obrixtamig - parenteral 2
- Enrollment: 306
- Primary outcome: Arm 1 and Arm 2: Maximum tolerated dose (MTD)
- Primary outcome: Arm 1 and Arm 2: Number of patients with DLTs in the MTD evaluation period

## Indexed commentary on NCT04429087 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct04429087